Opsona Therapeutics wins EC research grant of €5.9m
For the clinical development of lead drug candidate OPN-305
Opsona Therapeutics is to receive €5.9m, one of the largest grants to be awarded by the European Union FP7 Health Programme, to lead a European consortium of research and clinical groups in the advancement of clinical trials for its lead drug candidate OPN-305 in solid organ transplantation.
Opsona is an Irish drug development company based in Dublin, which focuses on novel therapeutic ways of treating autoimmune and inflammatory diseases.
The focus of the Monoclonal Antibody Solid Organ Transplantation (MABSCOT) trial will be on Delayed Graft Function (DGF), a complication of the immediate post-operative period in kidney transplants.
A Phase I trial in healthy volunteers is due to start this summer. Following successful completion of this trial, the consortium plans to carry out a randomised placebo-controlled Phase II trial in the prevention of DGF in 2012.
